7-Nitroindazole and methylene blue, inhibitors of neuronal nitric oxide synthase and NO-stimulated guanylate cyclase, block MK-801-elicited behaviors in mice

Neuropsychopharmacology

Volumn 15, Issue 1, 1996, Pages 37-43

  Deutsch, Stephen I ^a,b   Rosse, Richard B ^a,b   Paul, Steven M ^c,d   Tomasino, Vincent ^a   Koetzner, Lee ^a   Morn, Cassandra B ^a   Mastropaolo, John ^a  

^a DEPARTMENT OF VETERANS AFFAIRS   (United States)

^b GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

7 Nitroindazole; Antipsychotic; Methylene blue; MK 801; Phencyclidine; Popping behavior

Indexed keywords

7 NITROINDAZOLE; DIZOCILPINE; GLUTAMATE RECEPTOR; GUANYLATE CYCLASE; METHYLENE BLUE; N METHYL DEXTRO ASPARTIC ACID; NITRIC OXIDE SYNTHASE; PHENCYCLIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; INTRAPERITONEAL DRUG ADMINISTRATION; JUMPING; MALE; MODEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCHIZOPHRENIA;

EID: 0030201026     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0893-133X(95)00153-5     Document Type: Article

References (34)

1. Akbarian S, Bunney WE, Potkin SG, Wigal SB, Hagman JO, Sandman CA, Jones EG (1993a): Altered distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase cells in frontal lobe of schizophrenics implies disturbances of cortical development. Arch Gen Psychiatry 50:169-177
2. Akbarian S, Vineula A, Kim JJ, Potkin SG, Bunney WE, Jones EG (1993b): Distorted distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase neurons in temporal lobe of schizophrenics implies anomalous cortical development. Arch Gen Psychiatry 50:178-186
3. Andreason NC, Arndt S, Swayze II V, Cizaldo T, Flaum M, O'Leary D, Ehrhardt JC Yuh WTC (1994): Thalamic abnormalities in schizophrenia visualized through magnetic resonance image averaging. Science 266:295-298
4. Babbedge RC, Bland-Ward PA, Hart SL, Moore PK (1993): Inhibition of rat cerebellar nitric oxide synthase by 7-nitroindazole and related substituted indazoles. Br J Pharmacol 110:225-228
5. Bodoni P (1899): Le bleu de methylene comme calmant chez les alienes. Semaine Med 7:56
6. Bredt DS, Snyder SH (1992): Nitric oxide, a novel neuronal messenger. Neuron 8:3-11
7. Das I, Khan NS, Canthaboo M, Puri BK, Sooranna SR, de Belleroche J, Hirsch SR (1995): Circulating L-arginine metabolites and platelet nitric oxide synthase in schizophrenics. Schizophrenia Research 15:55
8. da Silva SV, da Silva VJ, Ballejo G, Salgado MC, Salgado HC (1994): Blockers of the L-arginine-nitric oxide-cyclic GMP pathway facilitate baroreceptor resetting. Hypertension 23(1 Suppl):160-163
9. Dawson TM, Dawson VL, Snyder SH (1992): A novel neuronal messenger molecule in brain: The free radical, nitric oxide. Ann Neurol 32:297-311
10. Dawson TM, Hung K, Dawson VL, Steiner JP, Snyder SH (1995): Neuroprotective effects of gangliosides may involve inhibition of nitric oxide synthase. Ann Neurol 37:115-118
11. Deutsch SI, Mastropaolo J, Schwartz BL, Rosse RB, Morihisa JM (1989): A "glutamatergic hypothesis" of schizophrenia: Rationale for pharmacotherapy with glycine. Clin Neuropharmacol 12:1-13
12. Deutsch SI, Hitri A (1993): Measurement of an explosive behavior in the mouse, induced by MK-801, a PCP analogue. Clin Neuropharmacol 16:251-257
13. Foster AC, Wong EHF (1987): The novel anticonvulsant MK801 binds to the activated state of the N-methyl-D-aspartate receptor in rat brain. Br J Pharmacol 91:403-409
14. Ferris RM, Harfenist M, McKenzie GM, Cooper B, Soroko FE, Maxwell RA (1982): BW 234 U, (cis-9-[3-3,5-dimethyl-1-piperazinyl) propyl] carbazole dihydrochloride: A novel antipsychotic agent. J Pharm Pharmacol 34:388-390
15. Iversen LL, Woodruff GN, Kemp JA, Foster AC, Gill R, Wong EHF (1989): Noncompetitive glutamate antagonists: Pharmacology and neuroprotective effects of the NMDA antagonist MK-801. In Barnard EA, Costa E (eds), Allosteric Modulation of Amino Acid Receptors: Therapeutic Implications. New York: Raven, pp 347-356
16. Javitt DC (1987): Negative symptomatology and the PCP (phencyclidine) model of schizophrenia. Hillside J Clin Psychiatry 9:12-35
17. Javitt DC, Zukin SR (1991): Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148:1301-1308
18. Khan NS, Das I, Puri BK, de Belleroche J, Hirsch SR (1995): Presence of a nitric oxide synthase inhibitor in schizophrenic subjects plasma. Schizophr Res 15:62-63
19. Karson CN, Garcia-Rill E, Biedermann J, Mrak RE, Husain MM, Skinner RD (1991): The brainstem reticular formation in schizophrenia. Psychiatr Res 40:31-48
20. Lipton SA (1993a): Prospects for clinically tolerated NMDA antagonists: Open-channel blockers and alternative redox states of nitric oxide. TINS 16:527-532
21. Lipton S, Choi Y, Pan Z, Lei S, Chen H, Sucher N, Loscalzo J, Singel D, Stamler J (1993): A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds. Nature 364:626-632
22. Lorrain D, Hull E (1993): Nitric oxide increases dopamine and serotonin release in the medial preoptic area. Neuropharmacol Neurotox 5:87-89
23. Martin W, Villani GM, Jothianandan D, Furchgott RF (1985): Selective blockade of endothelium-dependent and glyceryl trinitrate-induced relaxation by hemoglobin and by me;thylene blue in the rabbit aorta. J Pharmacol Exp Ther 232:708-716
24. Mayer B, Brunner F, Schmidt K (1993): Novel actions of methylene blue. Eur Heart J 14(Suppl 1):22-26
25. i values. J Pharmacol Exp Ther 251(1):238-246
26. Meltzer HY (1991): The mechanism of action of novel anti-psychotic drugs. Schizophr Bull 17:263-287
27. Moncada S, Higgs A (1993): The L-arginine-nitric oxide pathway. N Engl J Med 329:2002-2012
28. Moore PK, Wallace P, Gaffen Z, Hart SL, Babbedge RC (1993): Characterization of the novel nitric oxide synthase inhibitor 7 nitro indazole and related indazoles: Antinociceptive and cardiovascular effects. Br J Pharmacol 110:219-224
29. Murad F (1994) The role of nitric oxide in modulating guanylyl cyclase. Neurotransmissions 10:1-4
30. Narsapur SL, Naylor GJ (1983): Methylene blue. A possible treatment for manic depressive psychosis. J Affective Disord 5:155-161
31. Rosse RB, Mastropaolo J, Koetzner L, Morn CB, Sussman DM, Deutsch SI (1995): Computerized measurement of MK-801-elicited hyperactivity and popping in mice. Clin Neuropharmacol 18:448-457
32. Schmidt WJ (1991): The glutamatergic system as a target of antipsychotic drug action. In Oliver B, Mos J, Slangen JL (eds), Animal Models in Psychopharmacology. Boston, Birkhauser Verlag, pp 289-293
33. Snyder SH, Bredt DS (1992): Biological roles of nitric oxide. Sci Am 266:68-77
34. Tsou K, Snyder GL, Greengard P (1993): Nitric oxide/cGMP pathway stimulates phosphorylation of DARPP-32, a dopamine-and cAMP-regulated phosphoprotein, in the substantia nigra. Proc Natl Acad Sci USA 90:3462-3465